Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment-Reference-Cited by-同舟云学术

Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment

Published:2016-11-16 Issue:1 Volume:470 Page:21-27
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Lhermitte Benoît^ORCID,Egele Caroline,Weingertner Noëlle,Ambrosetti Damien,Dadone Bérengère,Kubiniek Valérie,Burel-Vandenbos Fanny,Coyne John,Michiels Jean-François,Chenard Marie-Pierre,Rouleau Etienne,Sabourin Jean-Christophe,Bellocq Jean-Pierre

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00428-016-2042-6.pdf

Reference9 articles.

1. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutation in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefinitib. N Engl J Med 350:2129–2139

3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13331

4. Smits AJ, Kummer JA, de Bruin PC, Bol M, van den Tweel JG, Seldenrijk KA, Willems SM, Offerhaus GJ, de Weger RA, van Diest PJ, Vink A (2014) The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol 27:168–174. doi: 10.1038/modpathol.2013.134

5. Viray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, Halling KC, Hameed M, Rimm DL (2013) A prospective, multi-institutional diagnostic trail to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med 137:1545–1549. doi: 10.5858/arpa.2012-0561-CP

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial intelligence algorithm for neoplastic cell percentage estimation and its application to copy number variation in urinary tract cancer;Journal of Pathology and Translational Medicine;2024-08-09

2. Optimization of Tumor Dissection Procedures Leads to Measurable Improvement in the Quality of Molecular Testing;The Journal of Molecular Diagnostics;2024-07

3. Artificial Intelligence and Lung Pathology;Advances in Anatomic Pathology;2024-05-23

4. Digital counting of tissue cells for molecular analysis: the QuANTUM pipeline;Virchows Archiv;2024-03-26

5. Determination of the Prevalence of Microsatellite Instability, BRAF and KRAS/NRAS Mutation Status in Patients with Colorectal Cancer in Slovakia;Cancers;2024-03-12